{"id":"https://openalex.org/W4388042485","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.1139","title":"1139 Efficacy of injectable antigen presenting nanoparticles (AIM INJ), in solid tumor models","display_name":"1139 Efficacy of injectable antigen presenting nanoparticles (AIM INJ), in solid tumor models","publication_year":2023,"publication_date":"2023-10-31","ids":{"openalex":"https://openalex.org/W4388042485","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.1139"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2023-sitc2023.1139","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.1139","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.1139","pdf_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/1253.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/1253.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100630634","display_name":"Haiyun Liu","orcid":"https://orcid.org/0000-0002-0485-2695","observed_orcids":["https://orcid.org/0000-0002-0485-2695"]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haiyun Liu","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Duong Nguyen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Duong Nguyen","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011016614","display_name":"Durgadas Cherukaraveedu","orcid":"https://orcid.org/0000-0002-2131-9083","observed_orcids":["https://orcid.org/0000-0002-2131-9083"]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Durgadas Cherukaraveedu","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101415013","display_name":"Adam R. Parks","orcid":"https://orcid.org/0009-0009-8646-0334","observed_orcids":["https://orcid.org/0009-0009-8646-0334"]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Parks","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104189758","display_name":"Bryan Hahn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bryan Hahn","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048422066","display_name":"Daniel Dembrow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Dembrow","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014527241","display_name":"Sojung Kim","orcid":"https://orcid.org/0000-0002-5747-1052","observed_orcids":["https://orcid.org/0000-0002-5747-1052","https://orcid.org/0000-0002-0252-7768","https://orcid.org/0000-0002-4599-6775"]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sojung Kim","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086237607","display_name":"Jack A. Ragheb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jack Ragheb","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020280484","display_name":"Aniket S. Wadajkar","orcid":"https://orcid.org/0000-0002-3968-8872","observed_orcids":["https://orcid.org/0000-0002-3968-8872"]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aniket Wadajkar","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024667876","display_name":"Mathias Oelke","orcid":"https://orcid.org/0000-0003-2253-6167","observed_orcids":["https://orcid.org/0000-0003-2253-6167"]},"institutions":[{"id":"https://openalex.org/I4210115701","display_name":"NexImmune (United States)","ror":"https://ror.org/02mczt252","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mathias Oelke","raw_affiliation_strings":["NeImmune Inc., Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeImmune Inc., Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210115701"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210115701"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A1253","last_page":"A1253"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.7229999899864197},{"id":"https://openalex.org/keywords/ot-i-t-cells","display_name":"OT-I T cells","score":0.9340000152587891},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.6690000295639038},{"id":"https://openalex.org/keywords/cd8-t-cell-expansion","display_name":"CD8+ T cell proliferation","score":0.8199999928474426},{"id":"https://openalex.org/keywords/anti-cd28-antibody","display_name":"anti-CD28","score":0.8840000033378601},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.652999997138977},{"id":"https://openalex.org/keywords/nanoparticle-size","display_name":"nanoparticle size","score":0.5789999961853027},{"id":"https://openalex.org/keywords/off-the-shelf-immunotherapy","display_name":"off-the-shelf immunotherapy","score":0.6759999990463257}],"concepts":[{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.6252003908157349},{"id":"https://openalex.org/C90375314","wikidata":"https://www.wikidata.org/wiki/Q3537484","display_name":"Adoptive cell transfer","level":4,"score":0.5929647088050842},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.542360782623291},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4911462962627411},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.48239102959632874},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.4677555561065674},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4369082450866699},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.4359411597251892},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.41047608852386475},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.370121568441391},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.30122536420822144},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2573646008968353},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.21761050820350647},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2023-sitc2023.1139","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.1139","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.1139","pdf_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/1253.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:c7c5ad681ce24a18840920432c03d5fc","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/c7c5ad681ce24a18840920432c03d5fc","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2023-sitc2023.1139","doi":"https://doi.org/10.1136/jitc-2023-sitc2023.1139","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2023-sitc2023.1139","pdf_url":"https://jitc.bmj.com/content/jitc/11/Suppl_1/1253.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4388042485.pdf","grobid_xml":"https://content.openalex.org/works/W4388042485.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4308394214","https://openalex.org/W6963750023","https://openalex.org/W3211443938","https://openalex.org/W4248661468","https://openalex.org/W3128523953","https://openalex.org/W4206230108","https://openalex.org/W2045127348","https://openalex.org/W1998948346","https://openalex.org/W4310163541","https://openalex.org/W4309245121"],"abstract_inverted_index":{"Background":[0],"NexImmune\u2019s":[1],"Artificial":[2],"Immune":[3],"Modulation":[4],"(AIM)":[5],"nanoparticle":[6],"(NP)":[7],"platform":[8],"(AIM":[9],"INJ)":[10],"is":[11],"an":[12,50,273,390],"injectable":[13],"multi-antigen":[14,69],"specific":[15,70,249],"off-the-shelf":[16,391],"immunotherapy":[17],"designed":[18],"to":[19,66,191,234,323,350],"directly":[20],"modulate":[21],"T":[22,77,152,196,208,259,301,377,383],"cell":[23,384],"responses":[24],"in":[25,121,133,198,261,265,307,332,358,370],"vivo.":[26,199,308],"It":[27],"consists":[28],"of":[29,57,84,99,111,187,201,206,221,247,256,311,339,345],"a":[30,37,46,61,68,134,340],"PLA-PEG":[31],"NP":[32,71,75,319],"conjugated":[33],"with":[34,45,60,88,142,223,237,279,330],"two":[35,124],"proteins,":[36],"dimeric":[38],"IgG":[39],"MHC-class":[40],"I":[41],"fusion":[42],"protein":[43],"loaded":[44,59,314],"tumor":[47,136,144,175,178,218,227,250,375],"peptide":[48],"and":[49,82,91,118,123,172,177,193,229,253,303,343,388,396],"anti-CD28":[51],"antibody":[52],"for":[53,354,362,386],"co-stimulation.":[54],"Multiple":[55],"batches":[56],"NPs,":[58],"single":[62],"peptide,":[63],"are":[64,79],"mixed":[65],"create":[67],"product.":[72],"AIM":[73,188,280,293,317,356,365],"INJ":[74,189,281,294,318,357,366],"expanded":[76],"cells":[78,103,153,197,209,260,302,378],"antigen-specific,":[80],"polyfunctional":[81],"consist":[83],"memory":[85,385],"phenotypes":[86],"associated":[87],"anti-tumor":[89,305],"activity":[90,306],"immunologic":[92],"memory.":[93],"Methods":[94],"We":[95,183],"performed":[96],"adoptive":[97],"transfer":[98],"OVA-TCR":[100],"transgenic":[101],"OT-1":[102,151,207,258],"into":[104,157,379],"C57BL/6":[105,138],"mice":[106,139,222,235,242],"followed":[107],"by":[108,372],"S.C.":[109,167],"injection":[110,176],"OVA":[112,248],"peptide-loaded":[113],"NPs.":[114,239],"NPs":[115,162,190,200,213,282,295],"between":[116],"35":[117],"90":[119],"nm":[120],"size":[122],"doses":[125],"were":[126,140,154,165],"tested.":[127],"To":[128],"further":[129,337],"evaluate":[130],"the":[131,158,185,284,316,380],"efficacy":[132],"solid":[135,363],"model,":[137,219],"implanted":[141],"B16F10-OVA":[143,217],"cells.":[145],"On":[146],"day":[147],"6,":[148],"1.5":[149],"million":[150],"adoptively":[155],"transferred":[156],"tumor-bearing":[159],"mice.":[160],"Control":[161],"or":[163],"OVA-NPs":[164,224,240],"injected":[166],"on":[168,315],"days":[169],"7,":[170],"14":[171],"21":[173],"after":[174],"volume":[179],"was":[180],"monitored.":[181],"Results":[182],"demonstrated":[184,264],"ability":[186],"activate":[192],"expand":[194,298],"antigen-specific":[195,299,376],"all":[202],"sizes":[203],"induced":[204],"expansion":[205],"while":[210],"non-specific":[211],"control":[212,238],"did":[214],"not.":[215],"In":[216],"treatment":[220],"significantly":[225,244],"delayed":[226],"growth":[228],"increased":[230],"survival":[231],"as":[232,263],"compared":[233],"treated":[236,241],"had":[243],"higher":[245,254],"amounts":[246],"infiltrating":[251],"lymphocytes":[252],"percentage":[255],"functional":[257],"spleen":[262],"ex":[266],"vivo":[267,333],"killing":[268],"assays.":[269],"Additional":[270],"data":[271],"from":[272],"ongoing":[274],"B16F10":[275],"mouse":[276],"melanoma":[277,286],"model":[278],"targeting":[283],"endogenous":[285],"antigen":[287],"gp100":[288],"will":[289,347],"be":[290,321,348],"presented.":[291],"Conclusions":[292],"can":[296,320],"activate,":[297],"CD8+":[300],"elicit":[304],"The":[309],"combination":[310],"antigen-peptide":[312],"targets":[313],"changed":[322],"address":[324],"different":[325],"tumors.":[326,364],"These":[327],"studies":[328,335,361],"along":[329],"other":[331],"pre-clinical":[334],"including":[336],"evaluation":[338],"dose":[341],"regimen":[342],"route":[344],"administration":[346],"used":[349],"support":[351],"our":[352],"INDs":[353],"using":[355,389],"Phase":[359],"1":[360],"potentially":[367],"addresses":[368],"gaps":[369],"immunotherapies":[371],"driving":[373],"multiple":[374],"tumor,":[381],"establishing":[382],"durability":[387],"modality":[392],"supporting":[393],"easier":[394],"access":[395],"scalability.":[397]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2023-11-01T00:00:00"}